Medicus Pharma (MDCX) Stock
What Medicus Pharma's price implies, from its SEC filings.
Key numbers
- P/E (forward)
- -0.08x
What Medicus Pharma's price implies
Medicus Pharma's free cash flow isn't comparable to its market value here, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Net income | -$5M | -$11M | -$47M |
| Free cash flow | — | — | — |
| EPS (diluted) | -$76.50 | -$58.00 | -$137.00 |
| Operating margin | — | — | — |
Superinvestors who own MDCX
From each investor's latest 13F filing (what a 13F shows).
None of the superinvestors we track held MDCX in their latest 13F.
Medicus Pharma insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you).
No open-market insider purchases of MDCX in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from MDCX's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
Questions about Medicus Pharma
Are Medicus Pharma insiders buying the stock?
No open-market insider purchases of MDCX in the last 12 months, according to SEC Form 4 filings.
Companies like Medicus Pharma
Amarin Corporation PLC (AMRN)$236MOrganon & Co (OGN)$3.6BGrifols SA ADR (GRFS)$5.7BBiogen Inc (BIIB)$36.7BGlaxoSmithKline PLC ADR (GSK)$101.0BSanofi ADR (SNY)$112.7BBristol-Myers Squibb Company (BMY)$127.0BNovo Nordisk A/S (NVO)$135.3BPfizer Inc (PFE)$167.5B All Healthcare stocks→Prices and ratios as of Nov 9, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.